On November 11, 2021, the board of directors of Bellerophon Therapeutics, Inc. appointed Peter Fernandes to serve as interim principal executive officer of the company, effective November 11, 2021, while the Board conducts a search for its next Chief Executive Officer. Mr. Fernandes currently serves as the company?s Chief Regulatory & Safety Officer and will additionally continue in that role. No family relationships exist between Mr. Fernandes and any of its directors or executive officers.